Indian Journal of Private Psychiatry

Register      Login

VOLUME 17 , ISSUE 1 ( January-June, 2023 ) > List of Articles

Original Article

Is there Any Relevance for the Use of Cyamemazine in the Treatment of Schizophrenia?

Leo Malandain, Florence Thibaut

Keywords : Antipsychotic treatment, Anxiety, Cyamemazine, Schizophrenia

Citation Information : Malandain L, Thibaut F. Is there Any Relevance for the Use of Cyamemazine in the Treatment of Schizophrenia?. Ind J Priv Psychiatry 2023; 17 (1):14-19.

DOI: 10.5005/jp-journals-10067-0128

License: CC BY-NC 4.0

Published Online: 10-02-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Introduction: Cyamemazine is widely used in the treatment of schizophrenia despite a potential risk of QT interval prolongation on electrocardiogram and weak evidence for its antipsychotic efficacy. The aim of our study was to compare the level of anxiety and the co-prescription of benzodiazepines and hypnotics in schizophrenic patients who received cyamemazine (alone or in association with other antipsychotics) with those who did not receive cyamemazine. Materials and methods: A total of 1,859 patients were enrolled according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia. We collected their medication prescriptions and assessment scale scores and compared patients receiving antipsychotic mono or polytherapy with or without cyamemazine at inclusion, 6-, and 12-months. As a comparison, we will use the same outcome measures in patients receiving loxapine or levomepromazine rather than cyamemazine. Results: Brief psychiatric rating score (BPRS) scale anxiety subscores of patients under monotherapy of cyamemezine at inclusion was lower than for other antipsychotic medications but the patients received higher doses of anxiolytics. No differences in psychotropic drug use or anxiety subscores were observed between patients on antipsychotic polytherapy whether cyamemazine was used or not at inclusion, 6-, and 12-months. Patients under antipsychotic polytherapy including cyamemazine had better Global Assessment of Functioning (GAF) scores than patients under polytherapy excluding cyamemazine. Comparison of cyamemazine, loxapine, and levomepromazine groups showed no statistically significant differences in co-prescription of psychotropic drug use or anxiety subscores at inclusion, 6-, and 12-months of follow-up, respectively. Conclusion: Our study does not find any evidence to recommend the use of cyamemazine in the anxiolytic or antipsychotic treatment in patients suffering from schizophrenia.

  1. Franck N, Thibaut F. Prescrire les antipsychotiques. Elsevier Masson, In 2015.
  2. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13(5):318–78. DOI: 10.3109/15622975.2012.696143.
  3. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14(1):2–44. DOI: 10.3109/15622975.2012.739708.
  4. Malandain L, Thibaut F, Grimaldi–Bensouda L, et al. Correlates and predictors of antipsychotic drug polypharmacy in real-life settings: Results from a nationwide cohort study. Schizophr Res 2017;192:213–218. DOI: 10.1016/j.schres.2017.05.015.
  5. Brunot A, Lachaux B, Sontag H, et al. Pharmaco–epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia. Encéphale 2002;28(2):129–138. PMID: 11972139.
  6. Gury C, Fabre C, Hameg A, et al. Prescription d'antipsychotiques en milieu hospitalier spécialisé. Inf Psychiatr 2006;82(6):503. DOI: 10.3917/inpsy.8206.0503.
  7. Benyamina A, Naassila M, Bourin M. Potential role of cortical 5-HT2A receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal. Psychiatry Res 2012;198(2):307–312. DOI: 10.1016/j.psychres.2012.01.009.
  8. Bourin M, Dailly E, Hascöet M. Preclinical and clinical pharmacology of cyamemazine: Anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. CNS Drug Rev 2006;10(3):219–229. DOI: 10.1111/j.1527-3458.2004.tb00023.x.
  9. Alvarez–Guerra M, d’Alché–Birée F, Wolf WA, et al. 5-HT3- and 5-HT2C-antagonist properties of cyamemazine: Significance for its clinical anxiolytic activity. Psychopharmacol Berl Janv 2000;147(4):412–417. DOI: 10.1007/s002130050010.
  10. Hameg A, Bayle F, Nuss P, et al. Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol 2003;65(3):435–440. DOI: 10.1016/s0006-2952(02)01515-0.
  11. Hodé Y, Reimold M, Demazières A, et al. A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian). Psychopharmacology (Berl) 2005;180(2):377–384. DOI: 10.1007/s00213-005-2172-z.
  12. Bourin M, Dhonnchadha NBA, Colombel MC, et al. Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Behav Brain Res 2001;124(1):87–95. DOI: 10.1016/s0166-4328(01)00238-8.
  13. Lal S, Nair NPV, Cecyre D, et al. Levomepromazine receptor binding profile in human brain – implications for treatment – resistant schizophrenia. Acta Psychiatr Scand 1993;87(6):380–383. DOI: 10.1111/j.1600-0447.1993.tb03391.x.
  14. Popovic D, Nuss P, Vieta E. Revisiting loxapine: A systematic review. Ann Gen Psychiatry 2015;14(1):15. DOI: 10.1186/s12991-015-0053-3.
  15. Poluzzi E, Raschi E, Koci A, et al. Antipsychotics and torsadogenic risk: Signals emerging from the US FDA Adverse Event Reporting System Database. Drug Saf 2013;36(6):467–479. DOI: 10.1007/s40264-013-0032-z.
  16. Bret P, Bret MC, Queuille E. Prescribing patterns of antipsychotics in 13 French psychiatric hospitals. Encéphale 2009;35(2):129–138. DOI: 10.1016/j.encep.2008.03.007.
  17. Arbus C, Benyamina A, Llorca PM, et al. Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci Off J Eur Fed Pharm Sci 2007;32(4–5):357–366. DOI: 10.1016/j.ejps.2007.09.003.
  18. Di Sciascio G, Calò S, Amodio G, et al. The use of first generation versus second generation antipsychotics as add-on or as switch treatment and its effect on QTC interval: The Italian experience in a real-world setting. Int J Immunopathol Pharmacol 2011;24(1):225–230.
  19. French High Authority of Health. Haute Autorité de Santé. Commission de la transparence. Avis du 2016. Cyamémazine tartrate. Paris: HAS; 2016.
  20. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 20:22–33;quiz 34-57. PMID: 9881538.
  21. Guy W. Clinical Global Impression. Rockville: National Institute for Mental Health, 1976, pp. 218–222.
  22. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;(10):799–812.
  23. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC, USA. 2000.
  24. Fond G, Resseguier N, Schürhoff F, et al. Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: Results from the national FACE-SZ cohort. Eur Arch Psychiatry Clin Neurosci 2018;268(6):541–553. DOI: 10.1007/s00406-017-0847-1.
  25. Thibaut F, Louchart S. Post-psychotic depression. Encephale 1999;25(Spec. 4):33–36. PMID: 10609109.
  26. Guerrero–Jiménez M, de Albornoz–Calahorro CMC, Girela–Serrano B, et al. Post-psychotic depression: An updated review of the term and clinical implications. Psychopathol 2022;55(2):82–92. DOI: 10.1159/000520985.
  27. Maynard GL, Soni P. Thioridazine interferences with imipramine metabolism and measurement: Ther Drug Monit 1996;18(6):729–731. DOI: 10.1097/00007691-199612000-00018.
  28. Mulsant M, Foglia JP, Sweet RA, et al. The effects of pherphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. J Clin Psychopharmacol 1997;17(4):318–321. DOI: 10.1097/00004714-199708000-00013.
  29. Suzuki T, Uchida H, Tanaka KF, et al. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: An open study of dose reduction for chronic schizophrenia. Int Clin Psychopharmacol 2003;18(6):323–329. DOI: 10.1097/00004850-200311000-00003.
  30. Achim AM, Maziade M, Raymond E, et al. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 2011;37(4):811–821. DOI: 10.1093/schbul/sbp148.
  31. Temmingh H, Stein DJ. Anxiety in patients with schizophrenia: Epidemiology and management. CNS Drugs 2015;29(10):819–832. DOI: 10.1007/s40263-015-0282-7.
  32. Malandain L, Leygues M, Thibaut F. Antipsychotic drug dose in real-life settings results from a Nationwide Cohort Study. Eur Arch Psychiatry Clin Neurosci 2022;272(4):583–590. DOI: 10.1007/s00406-021-01322-3.
  33. Hung GBK, Cheung HK. Predictors of high-dose antipsychotic prescription in psychiatric patients in Hong Kong. Hong Kong Med J 2008;14(1):35–39. PMID: 18239241.
  34. Gattetly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016;50(5):410–472. DOI: 10.1177/0004867416641195.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.